Inspired by nature, CiMaas will bring two arms of the immune system together to enhance the killing capacity of the system as a whole: inducing anti-cancer capacity of killer cells and strengthen its response by the use of antibodies. These technologies can be applied to a broad range of cancers.

    • The CiMaas tumor target dendritic cell vaccination platform provides extremely potent and patient specific dendritic cells that can effectively prime a specific anti-tumor T cell immune response with tumor cell-killing capacity superior to all other competitor products presently under study. CiMaas will actively explore the synergy between marketed immune cell checkpoint inhibitor monoclonal antibodies that enhance the immune response of the patient and dendritic cell vaccination to prime anti-tumor immunity. Checkpoint inhibitors fail in a large proportion of patients as single intervention. It is expected that the combination of these technologies will induce unsurpassed clinical responses and therefore will also be more cost-effective than single treatments due to the expected increase in life expectancy.
    • CiMaas is developing a new NK cell expansion technology to provide the capability for the treatment of cancer patients with very high numbers of donor derived Natural Killer cells (“NK cells”) that have a strong potency to kill tumor cells, already proven in several pre-clinical models. Donor NK cells are far more potent and active than the patients’ own NK cells. Also in this concept, CiMaas will combine this technology with targeting antibodies that bring these NK cells to the vicinity of tumor cells ánd provide an even stronger activation. For this, CiMaas will make use of existing antibody therapeutic products to obtain a superior efficacy.